“Good sleep promotes attention, memory consolidation, executive functions, including decision making, emotional control and mood,” Prof. Bassetti explained [1]. Sleep also functions as a sensory threshold and possibly modulates pain. Sleep promotes motor learning, behaviour, performance, and well-being. Among the mechanisms by which sleep helps to achieve this are energy saving, protein synthesis, membrane repair, synaptic plasticity and brain clearance.
Synaptic plasticity allows sleep-dependent synaptic downscaling. Synaptic strength increases during the major wake phase, followed by a synaptic down-selection while asleep. The reason for this “renormalisation” is that synapses cannot multiply and synaptic activity cannot increase indefinitely. The other theory Prof. Bassetti mentioned was brain clearance (“detoxification”) of the brain: the notion that proteins, including toxic proteins like amyloid and tau, are removed during sleep. Sleep deprivation has been associated with tau as well as amyloid increase in the central nervous system.
Yet another reason why sleep is important for the brain is that it consolidates memories. Replay of memories during sleep promotes learning; sleep deprivation is associated with reduced cognitive performance.
One of the implications of these insights is that sleep-wake can be the first (or primary) manifestation of neurological disorders. Examples are REM sleep behaviour disorders and pontomedullary dysfunction as a sign of synucleinopathies, and hypersomnia following a paramedian thalamic stroke.
Another implication is that sleep-wake disturbances are frequent in many neurological disorders (especially in the advanced stages), such as stroke, Parkinson's disease, Alzheimer's disease, epilepsy, migraine, autoimmune and neuromuscular disorders. “In the assessment of neurological disorders, it is mandatory to consider sleeping disorders: they are very frequent,” said Prof. Bassetti. Sleep disturbances can also be risk factors and modulators of neurological disorders. Examples are sleep apnea, insomnia and long sleep as risk factors of stroke, and the association between sleepiness and sleep apnea and the risk of dementia. Sleep enhancement improves neurological disorders in animal models.
Sleep is one of the fields in neurology in which precise approaches have begun to be applied: precise sleep-wake medicine, concluded Prof. Bassetti. Examples are orexin agonists in narcolepsy and antagonists in insomnia. “This is only the beginning.”
- Bassetti C. Sleep by the brain, for the brain: Implications for neurology. PLEN2, EAN Congress 2025, 21-24 June, Helsinki, Finland.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Letter from the Editor Next Article
OX2R agonists are a promising causal treatment of narcolepsy »
« Letter from the Editor Next Article
OX2R agonists are a promising causal treatment of narcolepsy »
Table of Contents: EAN 2025
Featured articles
Letter from the Editor
Lecanemab in AD: not a paradigm shift, but a small step forward
Epilepsy
SUDEP is an underreported cause of death in epilepsy patients
Stroke
Significant impact of implementing thrombectomy in Spanish stroke centres
Sleep
OX2R agonists are a promising causal treatment of narcolepsy
Neurologists must wake up to the importance of sleep
Infectious Diseases
Virus-specific T cells show promise in treating PML
Parkinson's disease
Encouraging results of adaptive DBS for Parkinson’s disease
Cognitive Impairment and Dementia
Dementia doubles the mortality risk 1 year after hip fracture
Lecanemab in AD: not a paradigm shift, but a small step forward
Headache and Migrane
GLP-1R agonists reduce migraine burden in obese patients
Occipital nerve stimulation is no more effective than placebo in cluster headache
Similar efficacy of anti-CGRP mAbs in short- and long-term migraine prevention
Why a good result of migraine treatment may not be good enough
Multiple Sclerosis
Rituximab does not halt progression in non-active secondary progressive MS
Real-world data confirms the effectiveness and safety of ofatumumab in MS
Comparable effectiveness and persistence of ocrelizumab and natalizumab
Muscle/Neuromuscular Disorders
Earlier add-on treatment in myasthenia gravis improves outcomes
Long-term benefits of cipa/mig in late-onset Pompe disease
Neuropathies
Is ChatGPT helpful in diagnosing polyneuropathies?
Riliprubart could be a new treatment option for CIDP
CAR T cell therapy shows promise in severe autoimmune neuropathies
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
